Belinostat (PXD101)

PXD101 (Belinostat) is a novel hydroxamate-type inhibitor of histone deacetylase activity. It inhibits HDAC activity in HeLa cell extracts with an IC50 of 27 nM. PXD101 is cytotoxic in vitro in a number of tumor cell lines with IC50s in the range 0.2-3.4 µM as determined by a clonogenic assay and induces apoptosis. This hdac inhibitor is currently under phase I/II testing in lymphoma, ovarian cancer and other solid tumors.

Synonyms: PXD101; PX105684; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide
Technical Data: Molecular Weight - 318.35; Molecular formula - C15H14N2O4S; CAS No - 414864-00-9

Ordering Information: Product Number - EC-000.2286; Price and Availability: Inquire This product is also available to buy in bulk quantities.

Related Products: Suberoylanilide Hydroxamic Acid; MS-275 (Entinostat); CI-994 (Tacedinaline); BML-210; M344; MGCD0103 (Mocetinostat); LBH-589 (Panobinostat); Tubastatin A; Scriptaid; NSC 3852; NCH 51; HNHA; BML-281; CBHA; Salermide; Pimelic Diphenylamide; ITF2357 (Givinostat); PCI-24781; APHA Compound 8; Droxinostat; SB939.

References:
1. Plumb JA, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003 Aug;2(8):721-8.
2. Zain JM, et al. Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol. 2010 Jun 10.
3. Ramalingam SS, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009 Jan;4(1):97-101.